Dr. Howard I. Scher, MD

Dr. Scher practices at Memorial Sloan Kettering Cancer Center in New York, New York.

Dr. Scher's NPI, 1689645533, was assigned on January 30, 2006. Dr. Scher graduated from New York University School of Medicine in 1976. Dr. Scher holds New York license 131278.

Dr. Scher's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Ave, New York, NY 10065 in New York County. The practice phone is (212) 639-2000.

Dr. Scher's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Scher to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Scher practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Scher's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Scher is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Scher's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists prostate cancer among the conditions Dr. Scher treats.

CMS data shows 78 Medicare services from Dr. Scher across 2 procedure codes in 2024, all of them office visits, for 26 Medicare patients. Medicare paid $7,389 for them. Every service was in an office.

CMS counts 26 Medicare patients who saw Dr. Scher in 2024. The largest group is 65 to 74, with 12 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Scher's median patient age at 76, with 14% women.

In 2024, Dr. Scher wrote 99 Medicare Part D claims for 15 patients. 21% of them were for generic drugs. CMS names the drug for 77 of them, across 2 drugs with 11 or more claims each, at $557,196 in total drug cost. In 2023, CMS named 105 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Scher for performance year 2024, reported as part of a group.

Dmand AI links 443 papers to Dr. Scher, published from 2002 to 2025. 2016 was the busiest year, with 23. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Prostate-Specific Antigen. Dr. Scher has published most often in J Clin Oncol. Dr. Scher's most frequent co-authors are Michael Morris, MD, Dana E. Rathkopf, MD and Wassim Abida, MD, PhD.

Dmand AI links Dr. Scher to 21 clinical trials, 10 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Esthesioneuroblastoma, Olfactory. Memorial Sloan Kettering Cancer Center sponsors the most, 12.

CMS Open Payments shows 107 general payments to Dr. Scher from 15 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. Pfizer Inc. paid the most, $28,743. It also lists 10 research payments totaling $21,238 from 2016 to 2021.

Dmand AI lists 9 awards for Dr. Scher, most recently Giants of Cancer Care in Genitourinary Oncology in 2023.

Dr. Scher graduated from New York University School of Medicine in 1976. Dr. Scher is a member of AOA, AACR, ACP and ASCO.

Dr. Scher is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.